RESUMO
@#BACKGROUND. To observe the efficacy and the safety of low-dose mitomycin-C (MMC) in the treatment of pterygium. MATERIAL AND METHODS. In a prospective, randomized and controlled clinical trial, a total of 550 eyes of 400 patients diagnosed with pterygium were randomly divided into the four groups - group 1:130 eyes of 100 patients without MMC; group 2:140 eyes of 100 patients , with 0.2g\L MMC; group 3:150 eyes of 100 patients, with 0.3g\L MMC; group 4:130 eyes of 100 patients, with 0.4g\L MMC. They underwent the excision of primary pterygium barely the sclera. Visual acuity, intraocular pressure (IOP), extraocular movement, iridocyclitis, scarring, symptoms (tearing, photophobia, foreign body sensation) and signs (conjunctival hyperemia, ulcer of sclera and cornea, perforation of sclera) of subjects, were recorded on the day of enrollment and after the surgery, on 2 weeks, 2 months, 6 months and 1 year. RESULTS. In a group 3 and 4, the recurrence of pterygium after the excision were less than that in group 1 and group 2 (р<0.01) . In a 4 group, after the surgery, there were more probability of raising IOP, iridocyclitis, symptoms and signs than that in group 1,2, and 3. СONCLUSION. Low dose MMC is effective in the treatment of preventing the recurrence of primary pterygium. It’s efficacy rises along with its density. And mean time, the safety of the treatment of low-dose MMC declines.
